Search clinical trials for: SHR1701

Total 31 results

Yuhan Corporation

Completed

Clinical Trial to Evaluate the Efficacy and Safety of YHP1701

Hypertension and Hyperlipidemia

Korea, Republic of
Yuhan Corporation

Completed

A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between YHR1705 and YHR1706

Type 2 Diabetes Mellitus | Dyslipidemia

Korea, Republic of
Chinese PLA General Hospital

Recruiting

Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas

Lymphoma | Solid Tumor

China
Chinese PLA General Hospital

Recruiting

SHR1701 Alone or in Combination With SHR2554 in Relapsed or Refractory Classical Hodgkin Lymphoma

Relapsed or Refractory Hodgkin Lymphoma

China
Shandong Cancer Hospital and Institute

Unknown

A Trial of SHR1701 Combined With Radiotherapy for Metastatic Non-small Cell Lung Cancer Failure After First-line Treatment

Non-Small-Cell Lung Cancer
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Trial of HR17031 Injection With Renal Insufficiency

Improved Glycemic Control in Patients With Type 2 Diabetes
Vietlife Healthcare Corporation
Vietnam National Cancer Hospital

Unknown

CH1701 for Prevention and Treatment of Radiation Burns (CH1701)

Cancer

Vietnam
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Clinical Study to Compare the Bioavailability of HR17031 in Healthy Subjects at Different Sites

Type 2 Diabetes

China
Peking University Cancer Hospital & Institute

Recruiting

To Explore the Efficacy and Safety of Camrelizumab Combined With SHR1020 in the Treatment of Advanced Melanoma

Melanoma

China
Fudan University

Recruiting

Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer (MULAN)

Breast Cancer | Metastatic Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Pharmacokinetics of HR17031 Injection in Healthy Subjects

Type 2 Diabetes Mellitus

China
Yong Chen

Recruiting

To Explore the Efficacy and Safety of SHR-1701 Combined With Temozolomide in the Treatment of Advanced Melanoma

Melanoma

China
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Trial of HR17031 Injection With Hepatic Insufficiency

Improved Glycemic Control in Patients With Type 2 Diabetes
Yuhan Corporation

Completed

BE Study of Two Formulations of Rivaroxaban 2.5 mg in Healthy Subjects

Healthy Volunteer

Korea, Republic of
Henan Cancer Hospital

Active, not recruiting

Camrelizumab Combined With FOLFOX Neoadjuvant Therapy for Resectable Gastric and Gastroesophageal Junctional Adenocarcinoma

Gastric Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Trial Comparing the Efficacy and Safety of HR17031 Injection to INS068 Injection and to SHR20004 Injection in Patients With Type 2 Diabetes

Type 2 Diabetes

China
Yanqiao Zhang
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Trial of SHR-1210 in Combination With Apatinib in Patients With Unresectable HCC (HZ-T-PD1-APA)

Hepatocellular Carcinoma
Qilu Hospital of Shandong University

Recruiting

Neoadjuvant Immunotherapy for Resectable Gastric Cancer

Gastric Cancer

China
Peking University

Unknown

PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell Lymphoma

NK/T-cell Lymphoma
Peking University Cancer Hospital & Institute

Unknown

PD-1 Antibody SHR-1210 Combined With Apatinib of First-line Treatment of Advanced Acral Melanoma

Melanoma

China
Hunan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study of Camrelizumab Combined With Chemotherapy as Neoadjuvant Therapy in Adcanced Esophageal Squamous Cell Carcinoma (ESCC)

Esophageal Squamous Cell Carcinoma

China
Henan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

SHR-1210 Combined With Epirubicin in the Treatment of Extensive Disease Small Cell Lung Cancer

Small Cell Lung Cancer Extensive Stage

China
Wuhan University

Recruiting

SBRT/LDRT in Combination With Camrelizumab and Apatinib in Metastatic Non-small Cell Lung Cancer Patient Previously Treated With PD-1/L1 Inhibitor and Chemotherapy (SABRE)

Non-Small Cell Lung Cancer

China
Peking University Cancer Hospital & Institute

Unknown

Camrelizumab Plus Apatinib and Temozolomide as First Line Therapy in Advanced Acral Melanoma

Melanoma
Hunan Cancer Hospital
Suzhou Sheng Diya Biomedical Co., Ltd.

Active, not recruiting

Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma

Adenocarcinoma of the Lung

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC.

Non-squamous Non-small-cell Lung Cancer

China
Sun Yat-sen University

Recruiting

First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer

Recurrent Cervical Cancer | Stage IVB Cervical Cancer | Persistent Cervical Cancer

China
Fudan University

Not yet recruiting

An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC in First-line Treatment (FUTURE-Trop2)

TNBC - Triple-Negative Breast Cancer
Fudan University
Chongqing University Cancer Hospital; Sun Yat-sen University; Peking University... and other collaborators

Recruiting

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Breast Cancer | Advanced Breast Cancer | Breast Neoplasm | HER2-negative Breast Cancer | Hormone Receptor Positive Tumor

China
Fudan University

Active, not recruiting

An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC. (FUTURE-SUPER)

TNBC - Triple-Negative Breast Cancer

China
Fudan University

Recruiting

FUSCC Refractory TNBC Umbrella (FUTURE) (FUTURE)

Triple-negative Breast Cancer

China

3

Subscribe